Clinical Development Director, Obesity/Cardiovascular

Role: Clinical Development Director for Amgen’s Obesity and Cardiovascular pipeline, focusing on late-phase studies of maridebart cafraglutide (AMG 133). Responsibilities: lead clinical strategy development, design and oversee global phase 3 trials, serve as medical monitor, review data, contribute to safety and regulatory interactions, author reports and publications, and engage with key opinion leaders. Requirements: MD or DO with at least 3 years of clinical research experience; preferred 5+ years in biotech/pharma, especially in cardiometabolic or related areas, with experience in late-phase trials, data review, and regulatory submissions. HighValue: obesity, cardiometabolic diseases, phase 3, biologics, clinical trial leadership, safety review, regulatory interactions, cross-functional collaboration. WorkSetup: not specified; likely hybrid or onsite based on location.